Ligand id: 804

Name: ancriviroc

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 72.08
Molecular weight 556.2
XLogP 5.43
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Compound class Synthetic organic
International Nonproprietary Names
INN number INN
8459 ancriviroc
SCH 351125
Database Links
BindingDB Ligand 50339956
CAS Registry No. 370893-06-4 (source: Scifinder)
ChEMBL Ligand CHEMBL78535
PubChem CID 9574343
Search Google for chemical match using the InChIKey ZGDKVKUWTCGYOA-URGPHPNLSA-N
Search Google for chemicals with the same backbone ZGDKVKUWTCGYOA
Search PubMed clinical trials ancriviroc
Search PubMed titles ancriviroc
Search PubMed titles/abstracts ancriviroc
Ancriviroc (SCH351125) is an orally available, small molecule antagonist of the C-C chemokine receptor type 5 (CCR5) expressed on T cells [4]. The compound was originally investigated as an anti-HIV therapeutic [4]. SCH351125-induced CCR5 blockade was investigated for action in treating rheumatoid arthritis, but with discouraging clinical trial results [6]. Other CCR5 antagonists (AZD5672 and maraviroc) have also proven ineffective in RA clinical trials [5].

There is some ambiguity in the literature and online databases as to the exact structure of ancriviroc. The structure shown here matches that in the PubChem entry linked to above, and as shown in [4], while other common representations of ancriviroc match CID 5479787.